Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys

[GlobeNewswire] – Chicago, IL — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week … more

View todays social media effects on RNA

View the latest stocks trending across Twitter. Click to view dashboard

See who Prosensa is hiring next, click here to view